TY - JOUR
T1 - Automated detection of neutropenia using non‐invasive video microscopy of superficial capillaries
AU - Pablo-Trinidad, Alberto
AU - Butterworth, Ian
AU - Ledesma‐Carbayo, María J.
AU - Vettenburg, Tom
AU - Sánchez‐Ferro, Álvaro
AU - Soenksen, Luis
AU - Durr, Nicholas J.
AU - Muñoz Barrutia, Arrate
AU - Cerrato, Carolina
AU - Humala, Karem
AU - Fabra Urdiol, Marta
AU - Del Rio, Candice
AU - Valles, Betsy
AU - Chen, Yi‐Bin
AU - Hochberg, Ephraim P.
AU - Castro‐González, Carlos
AU - Bourquard, Aurélien
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Cancer patients undergoing cytotoxic chemotherapy are at elevated risk of developing serious infections. The risk of developing these infections increases when white blood cell (WBC) count, particularly the absolute neutrophil counts (ANC), are reduced. This reduction in neutrophil counts, the most abundant white-blood-cell subtype, is referred to as neutropenia, with these infection episodes termed febrile neutropenia (FN). Patients have a high risk of developing FN during sustained severe neutropenia (ANC<500/μL), which is a common side effect of cytotoxic chemotherapies. FN occurs frequently, currently in approximately one in six of all chemotherapy patients, and it is associated with a high rate of mortality, where 11% of patients die after one or several hospitalizations. In the US alone, the
associated cost due to such hospitalizations accounts for $2.7B dollars annually, contributing to up to 40% of the total cost of cancer treatments.
AB - Cancer patients undergoing cytotoxic chemotherapy are at elevated risk of developing serious infections. The risk of developing these infections increases when white blood cell (WBC) count, particularly the absolute neutrophil counts (ANC), are reduced. This reduction in neutrophil counts, the most abundant white-blood-cell subtype, is referred to as neutropenia, with these infection episodes termed febrile neutropenia (FN). Patients have a high risk of developing FN during sustained severe neutropenia (ANC<500/μL), which is a common side effect of cytotoxic chemotherapies. FN occurs frequently, currently in approximately one in six of all chemotherapy patients, and it is associated with a high rate of mortality, where 11% of patients die after one or several hospitalizations. In the US alone, the
associated cost due to such hospitalizations accounts for $2.7B dollars annually, contributing to up to 40% of the total cost of cancer treatments.
UR - http://www.scopus.com/inward/record.url?scp=85067409963&partnerID=8YFLogxK
UR - https://discovery.dundee.ac.uk/en/publications/3da34cac-2eb5-481a-a181-507356614c15
U2 - 10.1002/ajh.25516
DO - 10.1002/ajh.25516
M3 - Letter
C2 - 31120579
SN - 0361-8609
VL - 94
SP - E219-E222
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 8
ER -
